Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, December 31, 2020.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2020 (2020-12-31): -774.92%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-258.22%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
BridgeBio Pharma, Inc.
Market Cap
$12.95B
Return on Equity (ROE)
N/A
TTM Avg
-258.22%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$12.89B
Return on Equity (ROE)
3.51%
TTM Avg
5.40%
3Y Avg
5.85%
5Y Avg
7.17%
Market Cap
$13.19B
Return on Equity (ROE)
7.78%
TTM Avg
17.97%
3Y Avg
19.27%
5Y Avg
21.22%
Market Cap
$12.52B
Return on Equity (ROE)
-17.13%
TTM Avg
-12.46%
3Y Avg
-8.76%
5Y Avg
-1.37%
Market Cap
$12.49B
Return on Equity (ROE)
10.49%
TTM Avg
6.83%
3Y Avg
5.29%
5Y Avg
3.21%
Market Cap
$12.17B
Return on Equity (ROE)
14.35%
TTM Avg
4.54%
3Y Avg
-6.13%
5Y Avg
-2.52%
Market Cap
$12.00B
Return on Equity (ROE)
23.91%
TTM Avg
22.63%
3Y Avg
21.83%
5Y Avg
21.13%
Market Cap
$14.16B
Return on Equity (ROE)
52.97%
TTM Avg
246.13%
3Y Avg
150.31%
5Y Avg
84.65%
Market Cap
$11.47B
Return on Equity (ROE)
N/A
TTM Avg
329.18%
3Y Avg
200.63%
5Y Avg
164.66%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | $12.95B | N/A | -258.22% | N/A | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 3.51% | 5.40% | 5.85% | 7.17% |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 7.78% | 17.97% | 19.27% | 21.22% |
| Baxter International Inc. (BAX)vs › | $12.52B | -17.13% | -12.46% | -8.76% | -1.37% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 10.49% | 6.83% | 5.29% | 3.21% |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 14.35% | 4.54% | -6.13% | -2.52% |
| Encompass Health Corporation (EHC)vs › | $12.00B | 23.91% | 22.63% | 21.83% | 21.13% |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | 52.97% | 246.13% | 150.31% | 84.65% |
| DaVita Inc. (DVA)vs › | $11.47B | N/A | 329.18% | 200.63% | 164.66% |
| Bio-Techne Corporation (TECH)vs › | $11.36B | 8.63% | 6.23% | 8.78% | 10.01% |
ROE
N/A
ROA
-57.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2020-12-31 | -774.92% |
| 2020-09-30 | -245.61% |
| 2020-06-30 | -130.31% |
| 2020-03-31 | -76.48% |
| 2019-12-31 | -63.78% |
| 2019-09-30 | -49.09% |
| 2019-03-31 | -62.58% |
